|Twitter summary from Canadian Society of Allergy and Clinic
|Page 1 of 1|
|Author:||mgreenspan [ Sat Nov 03, 2012 8:18 am ]|
|Post subject:||Twitter summary from Canadian Society of Allergy and Clinic|
In an EMS study, only 46% of participants recognized epinephrine as the drug of first choice for anaphylaxis. Only 36% recognized intramuscular (IM) epinephrine as the optimal route.
The new Epi device is called Auvi-Q in the U.S. (https://www.auvi-q.com). Will be called Allerject in Canada and released in early 2013. Who likes the U.S. name?
Allerject device may have a slightly shorter needle length in the pediatric dose (0.15 mg).
Allerject has a 5 second countdown (spoken aloud) once needle activated to inform user how long the device needs to be in place. Allerject needle is retractable after injection and tells you if dose is successful.
http://allergynotes.blogspot.ca/2012/10 ... -from.html
|Author:||walooet [ Sun Nov 04, 2012 11:10 am ]|
|Post subject:||Re: Twitter summary from Canadian Society of Allergy and Cli|
This is so exciting to have some alternatives for epinephrine --- pricing should lower and aesthetics should improve!
|Page 1 of 1||All times are UTC - 4 hours|
|Powered by phpBB® Forum Software © phpBB Group